Polifarma Ranks 92nd Among Top 500 Companies

Polifarma ranked 92nd in the 'Turkey's Second 500 Largest Industrial Enterprises - 2021' research prepared by Istanbul Chamber of Industry. Istanbul Chamber of Industry announced the results of its 'Turkey's Second 500 Largest Industrial Enterprises - 2021' research, based on net sales from production. Polifarma, a 100% domestically-owned company that has contributed to public health and the health sector for 36 years in Turkey, achieved the success of entering the list at rank 92. Polifarma's net sales from production, the main sizing criterion for ISO's Second 500 companies, reached TRY 848.9 million. Working to reduce Turkey's external dependency and ensure easy access to medicines, Polifarma Pharmaceutical, which exports to more than 70 countries, is Turkey's most preferred brand in the pharmaceutical, serum and hospital products sector. Polifarma Pharmaceutical manufactures medicines for many therapeutic areas including anesthesia, intensive care, infection, oncology, radiology, dialysis and cardiology, as well as critical serum products. It has production in ampoule, vial and PFS forms with approximately 600 registered products across all formats. In addition to being the market leader in serum production, it is rapidly developing its IV (intravenous) pharmaceutical portfolio while continuing its growth in the prescription markets segment. About Polifarma's journey, Turkey's most preferred brand in hospital products, began when the late Pharmacist Necdet Nuri Kumrulu became a partner in Aroma Pharmaceutical, founded in 1963, in 1983, and subsequently acquired the company in 1992, continuing operations under the same name. Today, as a 36-year-old, 100% domestically-owned pharmaceutical company, it is rapidly developing its IV (intravenous) pharmaceutical portfolio alongside being the market leader in serum production. As of 2021, it continues to grow in the prescription markets it has entered.